Get started
Author

Paul Russell

Observed names: P Russell, Paul G. Russell
ORCID: 0000-0002-7768-5701
Observed ORCID: 0000-0002-7768-5701
OpenAlex ID: A5013896238
RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-α and -γ selectivity, suppresses COPD inflammation
2017 · Catherine E. Charron, Paul Russell, et al. · European Respiratory Journal · 54
Single doses of p38 MAP kinase inhibitors or prednisolone affect CRP and IL-6 in patients with active Rheumatoid Arthritis (RA)
2012 · Pauline T. Lukey, Hayley C. Perry, et al. · Open Journal of Immunology · 9
PDF
Safety, pharmacokinetic and pharmacodynamic profile of RV568, a narrow spectrum kinase inhibitor, following repeat inhaled dosing in COPD patients
2013 · Paul Russell, Lindsey Cass, et al. · European Respiratory Journal · 4
ETD001: A long-acting inhaled ENaC blocker, is well tolerated in humans
2022 · P Russell, K Woodward, et al. · European Respiratory Journal · 3
PUR1800 (RV1162), A novel narrow spectrum kinase inhibitor, but not Fluticasone, reduces TNFa-induced cytokine release by primary bronchial epithelial cells from healthy volunteers and COPD patients
2018 · Aidan Curran, Catherine Charron, et al. · European Respiratory Journal · 1
Randomized, phase I studies to evaluate the safety, tolerability, and pharmacokinetics of an inhaled, TMEM16A potentiator, GDC-6988, in healthy subjects
2025 · Paul Miller, Daniel Repplinger, et al. · Therapeutic Advances in Respiratory Disease
Author response for "Randomized, phase 1 studies to evaluate the safety, tolerability, and pharmacokinetics of an inhaled, TMEM16A potentiator, GDC-6988, in healthy subjects"
2025 · Paul Miller, Daniel Repplinger, et al. · Publons reviews and discussion
LATE-BREAKING ABSTRACT: Safety, pharmacokinetic and pharmacodynamic profile of RV1162, a narrow spectrum kinase inhibitor, in healthy subjects and COPD patients
2015 · Paul Russell, Chris Stevenson, et al. · European Respiratory Journal
Works count: 8
Citation count: 71
H-index: 3
I10-index: 1
Year
Topic
Type